UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 466 - 480 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

SUFU 2008 Winter Meeting - Highlights of the BPH Podium Session
Tuesday, 04 March 2008
MIAMI, FL (UroToday.com) - Dr. Kracker from Columbia University reviewed the controversial role of urodynamics (UDS) as it pertains to diagnosis and management of lower urinary tract symptoms (LUTS) in men.
Login to read more...

Safety of Prolonged Sacral Neuromodulation Tined Lead Testing - Abstract
Thursday, 28 February 2008
Department of Urology, University of Bern, Bern, Switzerland.
read more

Symptom Bother and Health Care-Seeking Behavior among Individuals with Overactive Bladder - Abstract
Wednesday, 27 February 2008
Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
read more

Reliability of the 24-h Sensation-Related Bladder Diary in Women With Urinary Incontinence - Abstract
Monday, 25 February 2008
Department of Urology, University of Antwerp, Antwerp, Belgium.
read more

The Evolution of Obstruction Induced Overactive Bladder Symptoms Following Urethrolysis for Female Bladder Outlet Obstruction - Abstract
Friday, 22 February 2008
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
read more

Overactive Bladder in Children Should be Strictly Differentiated From Monosymptomatic Nocturnal Enuresis - Abstract
Wednesday, 20 February 2008
Department of Urology, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
read more

A Simple Validated Scale to Measure Urgency - Abstract
Monday, 18 February 2008
Department of Medicine, Archway Campus, Whittington Hospital, University College London and Department of Urology, Whittington Hospital, London, United Kingdom.
read more

Defining Overactive Bladder as Hypersensitivity
Thursday, 14 February 2008
BERKELEY, CA (UroToday.com) - Overactive bladder (OAB) has been defined by the International Continence Society (ICS) as urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection, or other obvious pathology.
read more

Health-Related Quality of Life and Sexual Function in Women with Stress Urinary Incontinence and Overactive Bladder - Abstract
Monday, 11 February 2008
Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
read more

Behavioral Therapies for Overactive Bladder: Making Sense of the Evidence - Abstract
Wednesday, 06 February 2008
Department of Obstetrics and Gynecology, Foothills Medical Centre, Calgary Alberta, Canada.
read more

WUF 2008 - Urodynamics and Reality
Saturday, 02 February 2008
Login to read more...

WUF 2008 - Stress Incontinence
Thursday, 31 January 2008
VAIL, CO (UroToday.com) - Most women have mixed incontinence even if stress incontinence is dominant.
Login to read more...

Pharmacological Effects of Propiverine and its Active Metabolite, M-1, on Isolated Human Urinary Bladder Smooth Muscle, and on Bladder Contraction in Rats - Abstract
Wednesday, 30 January 2008
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
read more

Pharmacological Analysis of the Interaction of Antimuscarinic Drugs at M(2) and M (3) Muscarinic Receptors in Vivo Using the Pithed Rat Assay - Abstract
Friday, 25 January 2008
Department of Pharmacology, Theravance, 901 Gateway Blvd., South San Francisco, CA, 94080, USA
read more

Sacral Nerve Stimulation: Neuromodulation for Voiding Dysfunction and Pain - Abstract
Friday, 25 January 2008
Department of Urology, University of Rochester, Rochester, New York 14642, USA.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder